<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01565395</url>
  </required_header>
  <id_info>
    <org_study_id>2011P000304</org_study_id>
    <nct_id>NCT01565395</nct_id>
  </id_info>
  <brief_title>Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>Xeomin</acronym>
  <official_title>Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Incobotulinum Toxin A&#xD;
      (Xeomin®) injections into the parotid and submandibular glands in patients with Parkinson's&#xD;
      Disease/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) with troublesome sialorrhea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be recruited if they have Parkinson's disease, Parkinsonism. Inclusion and&#xD;
      exclusion criteria are summarized below. Participants will be screened at the first visit to&#xD;
      make sure they are eligible for the trial. They will then undergo baseline testing including&#xD;
      neurologic evaluation, questions to assess their memory and cognitive status and evaluation&#xD;
      of their disease status using parts of the Unified Parkinsons's Disease Ratings Scale (UPDRS)&#xD;
      that are routinely used to follow disease progression. They will be given a questionnaire to&#xD;
      evaluate the severity of their drooling. Their saliva production will be measured by having&#xD;
      them spit into a cup for 5 minutes, twice.&#xD;
&#xD;
      At the first visit, after making sure they are eligible for the study and performing the&#xD;
      baseline testing and procedures, they will be given either Xeomin or placebo (saline&#xD;
      injections without medication) injections in the 4 glands that produce saliva. They will not&#xD;
      know which injection they received. This visit will take about 2 hours. They will be followed&#xD;
      up every month and asked about side effects, have neurologic evaluation and ALS-FRS testing&#xD;
      and fill-in the questionnaire for drooling severity. Saliva volume will be measured as done&#xD;
      at the first visit. At either Month 4 or 5, participants will receive the second injection.&#xD;
      This will be a &quot;cross-over&quot; injection, i.e., if they received Xeomin at the first injection&#xD;
      they will receive saline at the second and vice versa. Thus, all participants will receive&#xD;
      the study medication Xeomin, either as the first injection or the second injection at 4&#xD;
      months or 5 months. The follow up after the second injection will be one monthly visit for 3&#xD;
      months, with similar evaluations as described above. The follow-up visit will take about 1&#xD;
      hour each.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Could not recruit ALS participants, hence ALS arm discontinued&#xD;
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in objectively measured salivary volume between baseline and one month post-injection in the Xeomin group as compared to placebo</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Xeomin Injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fifteen units (0.15 ml) of incobotulinum toxin A injected into each parotid gland and 20 units (0.2 ml) to each submandibular gland for a total dose of 70 units using anatomical landmarks for ALS Twenty units (0.2ml) injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks for PD/parkinsonism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.15 ml sterile 0.9% saline injected into each parotid gland and 0.2 ml to each submandibular gland using anatomical landmarks for ALS 0.2ml injected into each parotid gland and 0.3 ml to each submandibular gland using anatomical landmarks for PD/parkinsonism</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Incobotulinum Toxin A</intervention_name>
    <description>Xeomin 70-100 units injected in the parotid and submandibular glands of subjects</description>
    <arm_group_label>Xeomin Injections</arm_group_label>
    <other_name>Xeomin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Sterile preservative free 0.9% saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Hypothesis: Xeomin® injections into the parotid and submandibular&#xD;
        glands are safe and effective in the treatment of troublesome sialorrhea in patients with&#xD;
        PD/Parkinsonism and ALS.&#xD;
&#xD;
        Inclusion criteria are as follows:&#xD;
&#xD;
        For ALS: 1. Patients diagnosed with ALS by el-Escorial Criteria, ages 20-80 with&#xD;
        troublesome sialorrhea as defined below**.&#xD;
&#xD;
        For PD/ Parkinsonism: 1. PD, Multiple Systems Atrophy (MSA), or Progressive Supranuclear&#xD;
        Palsy (PSP) diagnosed by clinical criteria, ages 20-80 with troublesome sialorrhea as&#xD;
        defined below**.&#xD;
&#xD;
        **Troublesome sialorrhea is defined as grade 3 or more (grade 3 is marked excess of saliva&#xD;
        with some drooling) or more on the UPDRS Part 2 Sialorrhea grading scale:[33] (Appendix 1)&#xD;
&#xD;
        For both groups:&#xD;
&#xD;
          1. Swallowing function: FOIS scale* 5 or greater (see appendix 1 for scale)&#xD;
&#xD;
          2. If patients have been treated with other medications for sialorrhea earlier, they&#xD;
             should be off the medications at least 4 weeks prior to the baseline evaluation.&#xD;
&#xD;
          3. If they are on other medications for sialorrhea at the time of the baseline&#xD;
             evaluation, the doses will be held stable throughout the period of the study.&#xD;
&#xD;
          4. Women of child bearing age will need to be on a reliable method of birth control for&#xD;
             the duration of the study.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        For both PD and ALS:&#xD;
&#xD;
          1. Current use of Coumadin&#xD;
&#xD;
          2. Concurrent significant medical illness.&#xD;
&#xD;
          3. History of myasthenia gravis or Lambert-Eaton Syndrome&#xD;
&#xD;
          4. Ongoing substance abuse&#xD;
&#xD;
          5. History of unreliable follow-up&#xD;
&#xD;
          6. Past use of Xeomin® or other botulinum toxin preparations&#xD;
&#xD;
          7. Cognitive impairment, defined as a score ≤ 23/30 on the Mini Mental Status Exam.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pushpa Narayanaswami, ME</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>March 26, 2012</study_first_submitted>
  <study_first_submitted_qc>March 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2012</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Pushpa Narayanaswami</investigator_full_name>
    <investigator_title>Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>PD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sialorrhea</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

